食管癌免疫治疗研究进展
Research Progress on Immunotherapy for Esophageal Cancer
DOI: 10.12677/ACM.2022.127998, PDF,   
作者: 杨 帅：延安大学，第一临床医学院，陕西 延安；许瑞彬*：延安大学附属医院，胸外科，陕西 延安
关键词: 食管癌；免疫治疗；联合治疗；Esophageal Cancer； Immunotherapy； Combination Therapy
摘要: 食管癌(Esophageal cancer, EC)是一种具有高度侵袭性且预后较差的恶性肿瘤，食管癌的发病率和死亡率均处于较高水平，严重威胁人类健康，目前，食管癌的标准治疗方案包括手术、放疗和化疗，尽管使用了多学科疗法，食管癌患者的预后仍不理想，5年总生存率仅为30%~40%，且目前尚无针对食管癌的特异性靶向药应用于临床。作为一种新的有效的癌症治疗手段，免疫治疗在食管癌治疗中具有广阔的应用前景。许多II、III期临床试验证实免疫治疗联合放化疗可以增强抗肿瘤作用。本文就目前免疫治疗在晚期食管癌中的临床研究展开论述。
Abstract: Esophageal cancer (EC) is a highly invasive malignant tumor with poor prognosis. The incidence and mortality of esophageal cancer are both at a high level, posing a serious threat to human health. Currently, the standard treatment plan for esophageal cancer includes surgery, radiotherapy and chemotherapy. Despite the use of multidisciplinary therapies, the prognosis of patients with esophageal cancer is still not ideal, the 5-year overall survival rate is only 30%~40%, and there is no specific targeted drug for esophageal cancer applied in clinic. As a new effective cancer treat-ment, immunotherapy has a broad application prospect in the treatment of esophageal cancer. Many phase II and III clinical trials have demonstrated that immunotherapy combined with chemoradiotherapy can enhance the antitumor effect. This article discusses the clinical study of immunotherapy in esophageal cancer.
文章引用：杨帅, 许瑞彬. 食管癌免疫治疗研究进展[J]. 临床医学进展, 2022, 12(7): 6922-6928. https://doi.org/10.12677/ACM.2022.127998

参考文献

[1] Lu, Y., Guan, L., Xu, M. and Wang, F. (2021) The Efficacy and Safety of Antibodies Targeting PD-1 for Treatment in Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis. Translational Oncology, 14, Article ID: 101083. [Google Scholar] [CrossRef] [PubMed]
[2] Luo, H., Lu, J., Bai, Y., Mao, T., Wang, J., Fan, Q., Zhang, Y., et al. (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 326, 916-925. [Google Scholar] [CrossRef] [PubMed]
[3] Zhang, B., Qi, L., Wang, X., Xu, J., Liu, Y., Mu, L., et al. (2020) Phase II Clinical Trial Using Camrelizumab Combined with Apatinib and Chemotherapy as the First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma. Cancer Communications, 40, 711-720. [Google Scholar] [CrossRef] [PubMed]
[4] Yu, R., Wang, W., Li, T., Li, J., Zhao, K., Wang, W., et al. (2021) RATIONALE 311: Tislelizumab Plus Concurrent Chemoradiotherapy for Localized Esophageal Squamous Cell Carci-noma. Future Oncology, 17, 4081-4089. [Google Scholar] [CrossRef] [PubMed]
[5] Shen, D., Chen, Q., Wu, J., Li, J., Tao, K. and Jiang, Y. (2021) The Safety and Efficacy of Neoadjuvant PD-1 Inhibitor with Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Journal of Gastrointestinal Oncology, 12, 1-10. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, H., Zhang, Q., Xu, M., Wang, L., Chen, X., Feng, Y., et al. (2020) CCL2-CCR2 Axis Recruits Tumor Associated Macro-phages to Induce Immune Evasion through PD-1 Signaling in Esophageal Carcinogenesis. Molecular Cancer, 19, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[7] Yuan, X., Zhang, A.Z., Ren, Y.L., Wang, X.L., Jiang, C.H., Yang, L., et al. (2021) Cytokine-Induced Killer Cells/ Dendritic Cells and Cytokine-Induced Killer Cells Immuno-therapy for the Treatment of Esophageal Cancer: A Meta- Analysis. Medicine, 100, Article ID: e24519. [Google Scholar] [CrossRef] 
[8] Wang, H., Xuan, T.-T., Chen, Y., Yu, H., Gu, T.-T., Zhou, G., et al. (2020) Investigative Therapy for Advanced Esophageal Cancer Using the Option for Combined Immunotherapy and Chemotherapy. Immunotherapy, 12, 697-703. [Google Scholar] [CrossRef] [PubMed]
[9] Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., et al. (2017) Prospects for Combining Targeted and Conventional Cancer Therapy with Immunotherapy. Na-ture Reviews Cancer, 17, 286-301. [Google Scholar] [CrossRef] [PubMed]
[10] Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al. (2019) Role of the Tumor Microenvironment in PD- L1/PD-1-Mediated Tumor Immune Escape. Molecular Cancer, 18, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[11] Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. [Google Scholar] [CrossRef] [PubMed]
[12] Liu, Y. and Cao, X. (2016) Immunosuppressive Cells in Tumor Immune Escape and Metastasis. Journal of Molecular Medicine, 94, 509-522. [Google Scholar] [CrossRef] [PubMed]
[13] Harris, S.J., Brown, J., Lopez, J. and Yap, T.A. (2016) Immu-no-Oncology Combinations: Raising the Tail of the Survival Curve. Cancer Biology & Medicine, 13, 171-193. [Google Scholar] [CrossRef] [PubMed]
[14] 马颖杰, 胡杰轩, 赵磊, 林海珊, 王婧, 等. 免疫治疗在晚期食管癌应用中的临床疗效及安全性分析[J]. 临床和实验医学杂志, 2022, 21(9): 955-959.
[15] Lin, Y.-T., Chen, Y., Liu, T.-X., Kuang, F. and Huan, P. (2021) Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squa-mous Cell Carcinoma. Cancer Management and Research, 13, 8219-8230. [Google Scholar] [CrossRef] 
[16] Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lu, A. and Zhang, G. (2016) A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences, 17, Article No. 1151. [Google Scholar] [CrossRef] [PubMed]
[17] Simsek, M., Tekin, S.B. and Bilici, M. (2019) Immunological Agents Used in Cancer Treatment. The Eurasian Journal of Medicine, 51, 90-94. [Google Scholar] [CrossRef] [PubMed]
[18] Hsieh, C.-C., Hsu, H.-S., Li, A.F.-Y. and Chen, Y.-J. (2018) Clinical Relevance of PD-L1 and PD-L2 Overexpression in Patients with Esophageal Squamous Cell Carcinoma. Journal of Thoracic Disease 10, 4433-4444. [Google Scholar] [CrossRef] [PubMed]
[19] Kollmann, D., Ignatova, D., Jedamzik, J., Chang, Y.-T., Jomrich, G., Baierl, A., et al. (2018) PD-L1 Expression Is an Independent Predictor of Favorable Outcome in Patients with Localized Esophageal Adenocarcinoma. Oncoimmunology, 7, Article ID: e1435226. [Google Scholar] [CrossRef] 
[20] Azuma, T., Yao, S., Zhu, G., Flies, A.S., Flies, S.J. and Chen, L. (2008) B7-H1 Is a Ubiquitous Antiapoptotic Receptor on Cancer Cells. Blood, 111, 3635-3643. [Google Scholar] [CrossRef] [PubMed]
[21] Hayashi, H. and Nakagawa, K. (2020) Combination Therapy with PD-1 or PD-L1 Inhibitors for Cancer. International Journal of Clinical Oncology, 25, 818-830. [Google Scholar] [CrossRef] [PubMed]
[22] Haanen, J.B. and Robert, C. (2015) Immune Checkpoint Inhibi-tors. In: Michielin, O. and Coukos, G., Eds., Progress in Tumor Research, Vol. 42, Karger, Basel, 55-66. [Google Scholar] [CrossRef] [PubMed]
[23] Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[24] Zhou, Y.-H., Li, J.-Y., Yan, J.-X., Guo, P., He, W.-W. and Liu, Y. (2022) Alleviation of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma and Its Relationship with Expression and Changes of PD-L1. Neoplasma. [Google Scholar] [CrossRef] 
[25] Muro, K., Kojima, T., Moriwaki, T., Kato, K., Nagashima, F., Kawakami, H., Ishihara, R., et al. (2022) Second-Line Pembrolizumab versus Chemotherapy in Japanese Patients with Advanced Esophageal Cancer: Subgroup Analysis from KEYNOTE-181. Esophagus, 19, 137-145. [Google Scholar] [CrossRef] [PubMed]
[26] Yan, X., Duan, H., Ni, Y., Zhou, Y., Wang, X., Qi, H., et al. (2022) Tislelizumab Combined with Chemotherapy as Neoadjuvant Therapy for Surgically Resectable Esophageal Can-cer: A Prospective, Single-Arm, Phase II Study (TD- NICE). International Journal of Surgery, 103, Article ID: 106680. [Google Scholar] [CrossRef] [PubMed]
[27] Huang, T.-X. and Fu, L. (2019) The Immune Landscape of Esophageal Cancer. Cancer Communications, 39, Article No. 79. [Google Scholar] [CrossRef] [PubMed]
[28] Huang, B., Shi, H., Gong, X., Yu, J., Xiao, C., Zhou, B., et al. (2021) Comparison of Efficacy and Safety between Pembrolizumab Combined with Chemotherapy and Simple Chemo-therapy in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma. Journal of Gastrointestinal Oncology, 12, 2013-2021. [Google Scholar] [CrossRef] [PubMed]
[29] Wu, Z., Zheng, Q., Chen, H., Xiang, J., Hu, H., Li, H., et al. (2021) Efficacy and Safety of Neoadjuvant Chemotherapy and Immunotherapy in Locally Resectable Advanced Esopha-geal Squamous Cell Carcinoma. Journal of Gastrointestinal Oncology, 13, 3518-3528. [Google Scholar] [CrossRef] [PubMed]
[30] Kato, K., Sun, J.-M., Shah, M.A., Enzinger, P.C., Adenis, A., Doi, T., et al. (2020) LBA8_PR Pembrolizumab Plus Chemotherapy versus Chemotherapy as First-Line Therapy in Patients with Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study. Annals of Oncology, 31, S1192-S1193. [Google Scholar] [CrossRef] 
[31] Kawazoe, A., Yamaguchi, K., Yasui, H., Negoro, Y., Azuma, M., Amagai, K., et al. (2020) Safety and Efficacy of Pembrolizumab in Combination with S-1 Plus Oxaliplatin as a First-Line Treatment in Patients with Advanced Gastric/ Gastroesophageal Junction Cancer: Cohort 1 Data from the KEYNOTE-659 Phase IIb Study. European Journal of Cancer, 129, 97-106. [Google Scholar] [CrossRef] [PubMed]
[32] Kojima, T., Hara, H., Tsuji, A., Yasui, H., Muro, K., Satoh, T., et al. (2022) First-Line Pembrolizumab  +  Chemotherapy in Japanese Patients with Advanced/Metastatic Esophageal Cancer from KEYNOTE-590. Esophagus. [Google Scholar] [CrossRef] [PubMed]

为你推荐